Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University ...

Moderna (NASDAQ:MRNA) executives highlighted progress on cost reductions, a ramp in international partnerships, and multiple late-stage pipeline milestones during the company’s fourth-quarter 2025 ...

The agency said it denied Moderna’s application because it refused to follow “very clear” guidance. The drugmakers says the FDA approved the design of its clinical trial.

A new study found no link between coronavirus vaccine and reduced female fertility.

Ultimately the committee must decide who is considered at high enough risk for an extra dose. Data provided by Pfizer and the ...

Moderna's and Merck's partnership could help to advance cancer care. A promising skin cancer trial might have broader implications for other types of tumor treatments. Five-year follow-up data from a ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed. The companies on Tuesday said the vaccine, in combination ...

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...

Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they ...

Moderna Inc. said its US Covid business did better than expected last year, a rare bright spot for the vaccine maker, which has struggled with the decline of people getting its shot. The number of ...

As 2025 winds to a close, we recall some of those who will not be with us as the new year begins, people — some famous, some less so — who died in the last 12 months after forging consequential lives ...

Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...